This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Intrapatient variation in molecular profiles at progression compared to baseline
Timeframe: From date of inclusion until the date of first documented progression (around 2 years)
longitudinal changes in VOCs profile and exosomes according to response to treatment
Timeframe: From date of inclusion until the date of first documented progression, assessed up to 2 years